182 related articles for article (PubMed ID: 34192419)
1. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa.
Thomas D; Kanefendt F; Schwers S; Unger S; Yassen A; Boxnick S
J Thromb Haemost; 2021 Oct; 19(10):2407-2416. PubMed ID: 34192419
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
Kubitza D; Heckmann M; Distler J; Koechel A; Schwers S; Kanefendt F
Br J Clin Pharmacol; 2022 Jul; 88(7):3447-3462. PubMed ID: 35014061
[TBL] [Abstract][Full Text] [Related]
3. First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
Nowotny B; Thomas D; Schwers S; Wiegmann S; Prange W; Yassen A; Boxnick S
J Thromb Haemost; 2022 Jul; 20(7):1684-1695. PubMed ID: 35490404
[TBL] [Abstract][Full Text] [Related]
4. BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics.
Thomas D; Thelen K; Kraff S; Schwers S; Schiffer S; Unger S; Yassen A; Boxnick S
Res Pract Thromb Haemost; 2019 Apr; 3(2):242-253. PubMed ID: 31011708
[TBL] [Abstract][Full Text] [Related]
5. The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers.
Xu J; Zhao N; Huang J; Li J; Zhao X; Xiang Q; Yang S; Dong Y; Wang H; Li Y; Yang G; Cui Y
Clin Drug Investig; 2023 Jun; 43(6):435-445. PubMed ID: 37326942
[TBL] [Abstract][Full Text] [Related]
6. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
[TBL] [Abstract][Full Text] [Related]
7. ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study.
Beale D; Dennison J; Boyce M; Mazzo F; Honda N; Smith P; Bruce M
Br J Clin Pharmacol; 2021 Aug; 87(8):3177-3189. PubMed ID: 33450079
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Kubitza D; Becka M; Voith B; Zuehlsdorf M; Wensing G
Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
[TBL] [Abstract][Full Text] [Related]
9. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
Perera V; Wang Z; Luettgen J; Li D; DeSouza M; Cerra M; Seiffert D
Clin Transl Sci; 2022 Feb; 15(2):330-342. PubMed ID: 34558200
[TBL] [Abstract][Full Text] [Related]
10. First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.
Chen R; Guan X; Hu P; Dong Y; Zhu Y; Zhang T; Zou J; Zhang S
Front Pharmacol; 2022; 13():821363. PubMed ID: 35222036
[No Abstract] [Full Text] [Related]
11. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Heitmeier S; Visser M; Tersteegen A; Dietze-Torres J; Glunz J; Gerdes C; Laux V; Stampfuss J; Roehrig S
J Thromb Haemost; 2022 Jun; 20(6):1400-1411. PubMed ID: 35289054
[TBL] [Abstract][Full Text] [Related]
12. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV; Kirsch B; Bhatt DL; Budaj A; Coppolecchia R; Eikelboom J; James SK; Jones WS; Merkely B; Keller L; Hermanides RS; Campo G; Ferreiro JL; Shibasaki T; Mundl H; Alexander JH;
Circulation; 2022 Oct; 146(16):1196-1206. PubMed ID: 36030390
[TBL] [Abstract][Full Text] [Related]
13. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
Perera V; Luettgen JM; Wang Z; Frost CE; Yones C; Russo C; Lee J; Zhao Y; LaCreta FP; Ma X; Knabb RM; Seiffert D; DeSouza M; Mugnier P; Cirincione B; Ueno T; Frost RJA
Br J Clin Pharmacol; 2018 May; 84(5):876-887. PubMed ID: 29346838
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose-escalation phase I study.
Zhang JY; Ruan ZR; Jiang B; Yang DD; Wang JY; Hu Y; Wang YR; Wang YM; Lin YF; Wang LL; Lou HG
Clin Transl Sci; 2024 Apr; 17(4):e13787. PubMed ID: 38558535
[TBL] [Abstract][Full Text] [Related]
15. SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.
Ma T; Dong Y; Huang L; Yang Y; Geng Y; Fei F; Xie P; Zhao Y; Lin H; Yang Z; Jin Y; Ju X; Sun R; Li J
Front Pharmacol; 2022; 13():1027627. PubMed ID: 36339534
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.
Yi BA; Freedholm D; Widener N; Wang X; Simard E; Cullen C; Al-Saady NM; Lepor NE; Coulter S; Lovern M; Bloomfield D
J Thromb Haemost; 2022 Feb; 20(2):307-315. PubMed ID: 34714969
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
[TBL] [Abstract][Full Text] [Related]
18. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI.
Schaefer M; Buchmueller A; Dittmer F; Straßburger J; Wilmen A
J Mol Biol; 2019 Dec; 431(24):4817-4833. PubMed ID: 31655039
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.
Kanefendt F; Thuß U; Becka M; Boxnick S; Berse M; Schultz A; Otto C
Clin Pharmacol Drug Dev; 2019 May; 8(4):467-479. PubMed ID: 29878583
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
